Blood bath in the markets, Sensex sheds 770 points
Blood bath in the markets, Sensex sheds 770 points

Blood bath in the markets, Sensex sheds 770 points

Bhagyashree Vivarekar Article rating: 5.0

Indian benchmark indices witness a free fall, both Nifty and Sensex shed 240 and 770 points, respectively. After hitting all-time high on January 29, benchmark indices tumbled nearly 3.5 per cent in just four trading sessions. 

Budget 2018: LTCG Tax explained
Budget 2018: LTCG Tax explained

Budget 2018: LTCG Tax explained

Raghav Bisani Article rating: 4.0

Long-term gain before January 31, shall not be taxable and capital loss shall be allowed to be set off (case when actual cost is higher than January 31).

Capital Trust reports healthy results
Capital Trust reports healthy results

Capital Trust reports healthy results

Rohan Takalkar Article rating: 3.0
Capital Trust reported healthy quarterly numbers in Q3FY18. The AUM and margins also showed stellar performance in the quarter. The NII for the quarter rose by 42.4 per cent yoy and 56.2 per cent qoq.
Godrej Properties posts weak bottom-line numbers
Godrej Properties posts weak bottom-line numbers

Godrej Properties posts weak bottom-line numbers

Amir Shaikh Article rating: 3.0

The PAT for the quarter came in at Rs. 25.94 crore, yoy decline of 66.4 per cent. This was also due to rise in effective tax rate to ~45 per cent from 34.4 per cent in Q3FY17.

Ten stocks close to their 52-week high
Ten stocks close to their 52-week high

Ten stocks close to their 52-week high

Shital Jibhe Article rating: 5.0

The markets on February 2 opened gap down. BSE Sensex is trading at 35,335.86, down by 570.80 points and the Nifty is trading at 10,850.40, down by 166.50 points.

Selling spree continues for Vakrangee, a trend reversal
Selling spree continues for Vakrangee, a trend reversal

Selling spree continues for Vakrangee, a trend reversal

Bhagyashree Vivarekar Article rating: 2.0

Vakrangee is on a selling spree in the markets since January 29. The free fall in the company's stock price was in the wake of possible investigation by SEBI for suspected share price and volume manipulation. the stock formed a kind of Shooting Star pattern at all-time high.

Lupin receives final approval to launch skin cream in US
Lupin receives final approval to launch skin cream in US

Lupin receives final approval to launch skin cream in US

Tanay Loya Article rating: No rating

Pharma major Lupin on Thursday announced receiving final nod from the US Food and Drug Administration (USFDA) to market its Clobetasol Propionate cream.

RSS
First30783079308030813083308530863087Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR